Kornimate/medical-research-clean huggingface dataset:
randomized trial of restrictive versus liberal perioperative fluid management for patients undergoing pancreatic resection

Conditions: Pancreatic Cancer

Summary: the purpose of this study is to help us learn what the best amount of fluid is that patients should receive during pancreas surgery. patients will receive either the liberal fluid amount for this surgery or a restricted fluid amount. both amounts of fluid have been used safely in patients having similar surgeries. these amounts have not been compared in pancreatic surgery. the fluids regimens that will be given are not experimental. this study will compare patients in the liberal and restricted fluid groups in terms of the nature of any surgical complications (problems)and recovery from surgery, including length of hospital stay.


Eligibility criteria:
inclusion criteria: * adults \> or = 18 years * patients scheduled for pancreaticoduodenectomy, central pancreatectomy or distal pancreatectomy. exclusion criteria: * pregnancy * history of active coronary disease unless a cardiac stress test showing no reversible ischemia and normal lv function within 30 days of operation * mi within 3 months * history of stroke * history of congestive heart failure and ejection fraction less than 35% * history of severe copd and resting oxygen saturation (spo2) \< 90% * renal dysfunction (cr \> 1.8) * abnormal coagulation parameters (inr \> 1.5 not on coumadin, or platelet * presence of active infection including hiv * bmi \> 35 * american society of anesthesiologists status \> iii, assigned at time of preoperative visit * corticosteroid use \> 10 mg prednisone/day * bilirubin \> 10.0

Keywords: pancreas surgery pancreaticoduodenectomy central pancreatectomy distal pancreatectomy resection iv fluids 09-185
asian botulinum clinical trial designed for early stroke spasticity

Conditions: Muscle Spasticity; Cerebrovascular Accident

Summary: the aim of this clinical study is to investigate the efficacy and safety of dysport® in patients with early onset of upper limb spasticity within 2-12 weeks after stroke.


Eligibility criteria:
inclusion criteria: * first-ever stroke according to the world health organisation criteria (previous transient ischaemic attack or clinically silent infarct on ct/mri is not counted as previous stroke) * ct/mri scan required to classify ischaemic / haemorrhagic stroke * patient recruited 2-12 weeks after stroke * modified ashworth spasticity score 1+ or above in either elbow or wrist joint exclusion criteria: * the patient has bleeding disturbances or having used coumarin derivatives * the patient is currently receiving drugs affecting neuromuscular transmission * co-existing severe systemic illness which may adversely affect the functional outcome * pre-existing neuromuscular junction disease or any neurogenic disorders which can interfere with spasticity
effect of acetyl-l-carnitine on chronic pancreatitis

Conditions: Chronic Pancreatitis

Summary: an open label pilot study will determine the effect of the amino acid nutritional supplement acetyl-l-carnitine (alc) on pain, quality of life, well-being, and serum pro-inflammatory mediator and oxidative stress levels in volunteers with chronic pancreatitis. the alc is given to all participants for 3 months, and assessments will occur at intake and after 3 months.

this is an open label pilot study to determine the effect of the amino acid nutritional supplement acetyl-l-carnitine (alc) on chronic pancreatitis. alc is an acetylated form of naturally occurring amino acid l-carnitine ((r)-3-acetyloxy-4-trimethylammonio-butanoate) found in red meat and is readily commercially available. supplementation with alc may decrease pain and improve overall health based on our preclinical treatment studies in rats with high fat and alcohol induced pancreatitis. in rats, alc reduces pain measures, improves glucose tolerance, decreases lipid peroxidation, and ki67 cellular injury biomarker, and improves pancreatic histopathology. the measurable outcomes of this clinical study are patients' questionnaire scores for: pain, quality of life, well-being, and serum pro-inflammatory mediator and oxidative stress levels in volunteers with chronic pancreatitis. the questionnaires are given at intake and at experiment end (3 months). participants will receive alc for 3 months. these findings will indirectly determine the effect of alc on the function and inflammatory state of the pancreas. currently, there is no specific therapy for chronic pancreatitis, and its pathophysiology is still poorly understood. it is known that chronic pancreatitis is caused by ongoing inflammation in the pancreas, yet, no pharmacological intervention exists that optimally addresses this. the broad actions of alc as an antioxidant and anti-inflammatory agent as well as its ability to reduce side-effects of alcohol cessation make it a perfect compound to pursue for the treatment of pancreatitis.

Eligibility criteria:
inclusion criteria: * only patients with chronic pancreatitis are included. exclusion criteria: * patients with pancreatic pseudocysts, abscesses, pseudoaneurysms, pancreatitic fistulas, pancreatic adenocarcinoma, * females that are pregnant or lactating * children are excluded. * patients suffering from seizure or thyroid disorders are also excluded due to possible exaggeration of their symptoms from taking alc according to manufacturer.

Keywords: pain depression cytokines well-being
a single center, phase i clinical trial to evaluate the safety of liztox inj in the treatment of post stroke upper limb spasticity

Conditions: Post Stroke Upper Limb Spasticity

Summary: * investigational product: liztox inj 100unit(hu-014) * title : a single center, phase i clinical trial to evaluate the safety of liztox inj in the treatment of post stroke upper limb spasticity * sites and investigators : asan medical center(seoul), min-ho chun, m.d, ph.d * objective : to evaluate the safety of liztox inj in the treatment of post stroke upper limb spasticity


Eligibility criteria:
inclusion criteria: * a subject who is diagnosed with stroke at least six weeks prior to screening. * a subject who has modified ashworth scale(mas) score which wrist flexor is ≥ 2 and flexor or finger flexor is ≥ 1. * a subject with a disability assessment scale(das)of at least ≥ 2 in one of the categories of hand hygiene, clothing, upper extremity, or pain for evaluation. exclusion criteria: * a subject who has medical history following. (allergy, chemodenervation(within 6 months), tendon lengthening(within 6 months), intrathecal baclofen.aspiration pneumonia, etc.) * a subject who has history of any diseases following. (neuromuscular junction disorder, nmj, myasthemia gravis, mg, lambert-eaton myasthenic syndrome, amyotrophic lateral sclerosis, als, skin disease, dysphagia, etc.) * from screening, subject who get a plastic surgery including fascioplasty, prosthesis implantation within 6 weeks * subject who takes a medication including skeletal muscle relaxants, aminoglycoside, lincomycin, anticholinergic drug, benzodiazepine, benzamide etc. * a subject who tend to bleed or are taking anti-coagulant drugs. * a sugject who is undergoing rehabilitation(physical therapy, occupational therapy, exercise therapy) or splinting in the area where medication for clinical trials is scheduled to be administered. * a sugject who has muscle atrophy, fixed joint/muscle contracture in the area where medication for clinical trials is scheduled to be administered. * any condition that, in the view of the investigator, would interfere with study participation.
fio2 in chronic obstructive pulmonary disease (copd) patient normobaric o2 versus niv

Conditions: COPD; Home Care; Oxygen Therapy

Summary: the purpose of this study is to compare pharyngeal fio2 in day time with nasal normobaric o2 with inhaled fio2 in the night time with home care ventilator niv at the same o2 flow.

in a prospective observational study the investigators will register fio2 in 15 voluntaries copd patients as following: * pharyngeal fio2 (g5® philips™ side stream fio2) with o2 supply through nasal cannula at basal flow (flow needed by patient). in order to compare fio2s the investigators will measure fio2 with 150%, 75%, 50% and 25 % of basal flow * and fio2 during nocturnal niv (pressure support ventilation; vivo 50®, bréas™), using facial or nasal masque (confort gel® respironics™). o2 flow will be basal flow.

Eligibility criteria:
inclusion criteria: * informed consent exclusion criteria: * acute on chronic respiratory distress

Keywords: home ventilator fio2 o2 niv copd
comparative study of muc5ac and muc2 mucins in tear film concentration in surgical treated pterygia patients

Conditions: Pterygium of Both Eyes

Summary: to identify and compare the differences in the concentration of the muc2 and muc5ac mucins in tear film in patients who underwent pterygium surgery using amniotic membrane transplantation and conjunctival autograft surgery.

patients with nasal, primary pterygium bigger than 1 mm of corneal invasion with residence in mexico city and older than 18 years were included. under informed consent, patients were divided into two groups in a random fashion. pterygium surgery was carried out with conventional technique performing amniotic membrane transplantation for group a, and conjunctival autograft for group b. muc2 and muc5ac mucin concentration was measure min tear film by elisa; samples were taken before surgery, at first, third and sixth month postoperatively. but was also measured on the same dates. descriptive statistics and the u-mann whitney test for independent groups, considering a p≤0.05 as significant were used for analysis.

Eligibility criteria:
inclusion criteria: * patients with nasal, primary pterygium bigger than 1 mm. exclusion criteria: * diabetes mellitus, single eye.

Keywords: pterygium, amniotic membrane, conjunctival autograft, ocular mucin
cognitive behavioral therapy program to first-episode psychosis patients and cannabis abuse

Conditions: First-episode Psychosis; Cannabis Abuse

Summary: general objective: to assess the effectiveness of a treatment program specific for cannabis abuse (cognitive behavioral treatment + pharmacological treatment) compared to standard treatment (pharmacological treatment + psychoeducation) in patients with first episodes psychosis (fep) cannabis users. design a multicenter single-blind randomized study with 1 year of follow-up. the effectiveness of a treatment program specific for cannabis abuse (cognitive behavioral treatment + pharmacological treatment) compared to standard treatment (pharmacological treatment + psychoeducation) in patients with first episodes psychosis (fep) cannabis users will be assessed. patients will be randomly assigned to one of two treatments: 1. experimental group (n=50): cognitive-behavioral treatment specific for cannabis abuse + pharmacological treatment 2. control group (n=50): standard treatment: psychoeducation + pharmacological treatment


Eligibility criteria:
inclusion criteria: 1. - having a first psychotic episode. dsm-iv-tr diagnosis of a psychotic disorder (i.e. schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, bipolar disorder, atypical psychosis, brief psychotic disorder, or major depressive disorder with psychotic symptoms). 2. - being a regular cannabis user according dsm-iv 3. -being in remission from the first psychotic episode (not exceeding 5 years). exclusion criteria: 1. presenting organic brain pathology. 2. presenting mental retardation according to dsm-iv criteria.
reperfusion treatment in acute pulmonary embolism

Conditions: Pulmonary Embolism

Summary: international guidelines recommend immediate reperfusion with systemic thrombolysis (st) as first-line treatment in high-risk pulmonary embolism (pe). the therapy improves hemodynamics and overall survival but is also associated with a significant risk of severe bleeding. catheter-directed intervention (cdi) is recommended as an alternative reperfusion therapy in high-risk pe when st is contraindicated or has failed, as well as in patients who deteriorate or fail to improve during anticoagulation (ac) treatment. despite lack of high-quality evidence and randomized studies between cdi and standard care, the use of cdi is spreading rapidly in high-risk pe and in less severe pe not fulfilling current treatment criteria.

several cdi methods are available, including mechanical thrombectomy (mt) and catheter-directed thrombolysis (cdt), but no method is currently recommended over the other. in sweden, the mt device flowtriever® (ft) was introduced in 2021 and has since then been the predominant method. industry sponsored trials have investigated ft in uncontrolled observational trials and primarily in intermediate-risk pe. the investigator-initiated research on ft is limited to relatively small, descriptive, single-arm studies, or trials focusing on intermediate-risk pe. there are several ongoing trials comparing different cdi methods to anticoagulation. however, in clinical practice, patients with acute pe may be subjected to different reperfusion strategies depending on severity and available resources. the pe-nordic observational study will compare the outcomes of different patient groups treated with current cdi methods used in the nordic countries to patients treated with st.

Eligibility criteria:
inclusion criteria: * all adult patients (≥18 years), including pregnant women, with verified (ctpa, angiography or scintigraphy) acute pulmonary embolism who are planned for, or have received, treatment with catheter directed intervention or systemic thrombolysis * informed consent (for patients who do not survive before informed consent can be obtained, a waiver of consent applies) exclusion criteria: * ongoing enrolment in interventional catheter directed intervention trial * surgical embolectomy as primary reperfusion treatment

Keywords: thrombolysis catheter-directed intervention aspirational thrombectomy catheter-directed tromboylsis high-risk pe
is clonal hematopoiesis of indeterminate potential associated with unprovoked pulmonary embolism?

Conditions: Pulmonary Embolism; Hematopoiesis

Summary: the clonal hematopoiesis of indetermined prognosis (chip) has been described as risk factor for juvenile atherosclerosis. moreover, some of chip genes are responsible of myeloproliferative disorders. venous thrombosis are frequent in these disorders. the purpose of this project is to determine if chip is frequent in unprovoked pulmonary embolism and could be part of the pathophysiology.


Eligibility criteria:
inclusion criteria: * for cases : previous proximal unprovoked pulmonary embolism, negative thrombophilia screening. * for control : previous proximal provoked pulmonary embolism, negative thrombophilia screening. exclusion criteria: * age superior to 65 years old, * active cancer

Keywords: pulmonary embolism hematopoiesis genetic sequencing endothelial dysfunction
understanding the spectrum of enpp1 deficiency and acute abcc6 deficiency

Conditions: Generalized Arterial Calcification in Infancy; Autosomal Recessive Hypophosphatemic Rickets Type 2

Summary: to date, the investigators lack characterization of, the burden of, and the systemic progression of disease in enpp1 deficiency and abcc6 deficiency from a patient and/or parent perspective. this study aims to document this characterization, progression as well as the burden of disease. link to the study registration- https://www.engagehealth.com/survey/takesurvey.aspx?surveyid=8252n62

this will be a comprehensive, cross-sectional study conducted in approximately 60 individuals (or representative parents of patients) affected by enpp1 deficiency and the acute form of abcc6 deficiency. all study participants will complete the rsvp, pro tools and upload a proof of disease form, followed by an interview conducted by a trained interviewer. it is estimated that each respondent will need up to 60 minutes for the entire process; 20 minutes to complete the rsvp, pro tools and to upload proof of diagnosis of enpp1 deficiency or the acute form of abbc6 deficiency, and approximately 40 minutes to complete the interview and address any follow-up questions if needed.

Eligibility criteria:
inclusion criteria: 1. participant must be a person with enpp1 deficiency or the acute infantile form of abcc6 deficiency who is 18 years or older 2. the parent/caregiver of a patient who has been diagnosed with enpp1 deficiency or the acute infantile form of abcc6 deficiency. please note, parents/caregivers of patients with enpp1 deficiency who have passed away may participate 3. confirmed diagnosis of enpp1 deficiency or abcc6 deficiency with written proof of disease provided 4. ability to participate in the rsvp and interview in german, french or english, irrespective of country of residence. 5. able to grant informed consent 6. willing to participate in a 40-to-60-minute telephone interview, including follow up questions (if necessary) exclusion criteria: * inability to meet any of the inclusion criteria

Keywords: enpp1 deficiency and abcc6 deficiency
additional 6-month safety follow-up after completion of precursor study 880801

Conditions: Prophylaxis of Ross River Virus Infection

Summary: the purpose of this study is to verify the long-term safety of a 2.5 µg, adjuvanted (aluminium hydroxide) dose of ross river virus (rrv) vaccine.


Eligibility criteria:
inclusion criteria: subjects who participated in precursor study 880801 and meet all of the following criteria: * subject received 3 rrv vaccinations in study 880801 * subject has completed visit 6 in study 880801 * subject and, if applicable, subject´s parent(s)/legal guardian(s), understand the nature of the study and its procedures, agree to its provisions and provide written informed consent prior to study entry * subject provides written assent according to his/her age, if applicable exclusion criteria: * subject has participated in another clinical study other than study 880801 involving an investigational product (ip) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an ip or investigational device during the course of this study
enhancing long-term smoking abstinence among cervical cancer survivors (project access)

Conditions: Smoking Cessation; Cervical Cancer; High Grade Cervical Dysplasia

Summary: the goal of this research study is to compare the efficacy of a treatment approach that comprises both motivation and problem-solving (maps)-based telephone counseling and a personally-tailored sms-delivered text-based approach to quitline-delivered smoking cessation treatment to help participants with a history of cervical cancer or high-grade cervical dysplasia quit smoking.


Eligibility criteria:
inclusion criteria: * at least 100 cigarettes or more smoked in participants lifetime * speaks english * currently smoke 1 cigarette or more in the past 30 days * history of cervical cancer or high grade cervical dysplasia * has a working smartphone * has a valid home address * reside in florida at the time of study enrollment exclusion criteria: * receiving behavioral or pharmacological tobacco treatment * household member enrolled in this study
weight loss and prevention in latina immigrants: advancing methods of community-based intervention delivery

Conditions: Weight Loss

Summary: the long-term objective of this study protocol is to develop and test a culturally sensitive, community-based intervention, esencial para vivir (essential for life) to promote weight loss and diabetes prevention among overweight or obese latina immigrants. we chose to focus on latinas because latinas are at especially high risk for developing diabetes and currently there are not spanish programs available in our area that provide education about weight management and diabetes prevention.

the 8-week weight loss program, esencial para vivir (essential for life), is comprised of 6 groups sessions and 2 individual sessions delivered by a bilingiual, bi-cultural community health advisor. all sessions are interactive with activities that build on educative content and most contain an interactive dvd component. we propose an innovative approach that will employ the dvd in tandem with our education sessions delivered by a community health advisor to maximize buy-in from participants as well as provide access to community health leaders (medical professionals - endocrinologists, internists, nutritionists). participants will be over 19 years of age, self-identifying as hispanic women without diabetes, not pregnant or have given birth within the previous six months. the participants will be recruited from jefferson county through community agencies and organization. participants will be recruited and screened with an initial contact sheet to ensure that they meet our criteria, then they will be consented and complete baseline measurements. at the completion of the program, participants will repeat measures done at baseline, and 6 months post program completion.

Eligibility criteria:
inclusion criteria: * female aged 19 years or older, * foreign born, self-identified as latina, * no history of diagnosed diabetes, * fasting blood sugar \ 25kg/m2). exclusion criteria: * any medical condition for which weight loss was contraindicated; a fasting glucose \> 126 mg/dl, * pregnancy, postpartum less than 6 months, or planning a pregnancy before the end of the study period.
a study to evaluate the efficacy of the nasal antiseptic, previnc, when administered for the riskreduction of rhinitis in subjects who work for child day care centers

Conditions: Upper Respiratory Infections

Summary: the hypothesis was to establish whether the use of previnc administered nasally 2-3 times a day will prevent upper respiratory infections in otherwise healthy adults working in child day care centers.


Eligibility criteria:
inclusion criteria: * subject must provide written informed consent prior to the conduct of any study * male or female * 18-65 years of age * inclusive * employed by one of seven selected day care centers exclusion criteria: * recent symptoms of upper respiratory infection, respiratory disease * received medication for colds or allergies within 3 weeks of enrolling * had nasal surgery within 2 months of enrolling * had a pierced nose or wore nose jewelry